Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung T. Le(Johns Hopkins University), Elizabeth M. Jaffee(Bloomberg (United States)), Paul E. Oberstein(Columbia University Irving Medical Center), Zev A. Wainberg(University of California, Los Angeles), Aimee Murphy(Aduro BioTech (United States)), Colin D. Weekes(Massachusetts General Hospital), Sandy Ferber(University of Illinois Chicago), Dan Laheru(Johns Hopkins University), Vincent J. Picozzi(Virginia Mason Medical Center), Benjamin Musher(Baylor College of Medicine), Nitya Nair(490 BioTech (United States)), Andrew H. Ko(University of California, San Francisco), Erkut Borazanci(HonorHealth), Herbert J. Zeh(Southwestern Medical Center), Michael A. Morse(Duke Medical Center), Amanda Enstrom(Aduro BioTech (United States)), Chan C. Whiting(Aduro BioTech (United States)), Todd S. Crocenzi(Providence Portland Medical Center), Hedy L. Kindler(University of Chicago), Dirk G. Brockstedt(Rapt Therapeutics (United States)), Noelle K. LoConte(University of Wisconsin Carbone Cancer Center), Tony Reid(University of California San Diego), Andrea Wang‐Gillam(Washington University in St. Louis)
Cited by 260
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k